Table 1.
Demographics | n (%) |
---|---|
| |
Subjects | 45 |
Children (2–12 years) | 32 (71.1%) |
Adolescent (12–21 years) | 13 (28.8%) |
Number of observations | |
Risperidone | 168 |
(−)-9-hydroxyrisperidone | 172 |
(+)-9-hydroxyrisperidone | 172 |
Sex | |
Male | 40 (88.9%) |
Female | 5 (11.1%) |
Race | |
White | 42 (93.3%) |
White + Black (mixed) | 3 (6.7%) |
Ethnicity | |
Non-Hispanic | 45 (100%) |
Age (years) | 9.6 ±3.7 (3–18.3) |
Weight (kg) | 43 ±20.2 (16.8–110) |
Mean ±SD (range) | |
Dose range (total daily dose, mg) | (0.25–6.00) |
Risperidone concentration (ng/mL) | 6.5 ±6.4 (0.14–30.1) |
(−)-9-hydroxyrisperidone (ng/mL) | 8.4 ±7.6 (0.5–44.0) |
(+)-9-hydroxyrisperidone (ng/mL) | 3.84 ±2.97 (0.4–12.6) |
CYP2D6 | n = 28 |
Phenotype | 15 extensive metabolizer |
6 intermediate metabolizer | |
7 poor metabolizer | |
Genotype | 5(*1/*1); 8(*1/*2A); 2(*1/*2); 2(*1/*41); 1(*1/*4); 1(*1/*5); 1(*1/*6); 1(*1/*9); 1(*4/*4DUP); 5(*4/*4); 1(*4/*5) |
SD = standard deviation; ng = nanograms; mL = millilitres; mg = milligrams; kg = kilograms; CYP2D6 = cytochrome P450 2D6; DUP = duplication.